EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

EssexBio Bolsters Commitment to Ophthalmology Innovation at APAO 2026 in Hong Kong

2026.02.10

EssexBio to Participate in APAO 2026 and Showcase Key Ophthalmology Assets

2026.01.22

EssexBio Forms Strategic Cooperation with Kenvue for Motrin®, Tylenol® and Rhinocort®

2025.12.17

Essex Bio-Technology establishes strategic collaboration with Biosparc Signs MOU with SIPIPO and Biosparc on International Innovation Accelerator

2025.11.21

Date

Title

2019-08-12

Essex Biotech's mid-2019 net profit increased by 31% year-on-year to HK$129 million

2019-08-02

Essex Bio-Technology and Antikor Biopharma Forge Strategic Alliance in FDC for Cancer Treatment

2019-07-19

Essex Bio-Technology and Mitotech Announce Topline Results from VISTA-1, Phase 3 Clinical Trial in U.S. FDA of a First-In-Class Drug for Dry Eye Disea

2019-05-15

Essex Bio-Technology Included by MSCI as A Constituent of The MSCI China Small Cap Index

2019-04-29

Essex Bio-Technology Announces Upcoming Joint Presentation with Mitotech and Ora at ARVO 2019 Annual Meeting

2019-03-12

FY18 Turnover & Net Profit grew 30.8% and 38.1% to HK$1,176.5 million & HK$ 231.1 million, respectively

2019-01-10

The cellular growth factor project of Essex Bio-Technology Limited was honoured with the second prize of National Scientific and Technology Progress Award

2018-10-30

Essex Bio-technology Entered into Convertible Notes Purchase Agreement and License Agreement with DB Therapeutics

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT